ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,721 to 1,740 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: All-cause Mortality68 of 2,526

87 of 2,526

-0.8 points

-1.7 to 0.2

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Thrombotic Stroke13 of 2,526

7 of 2,526

0.2 points

-0.1 to 0.6

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Stent Thrombosis34 of 2,526

32 of 2,526

0.1 points

-0.6 to 0.7

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding104 of 2,526

127 of 2,526

-0.9 points

-2.1 to 0.2

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Coronary Revascularisation286 of 2,526

259 of 2,526

1.1 points

-0.6 to 2.8

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Myocardial Infarction (Fatal and Non-fatal)221 of 2,526

203 of 2,526

0.7 points

-0.8 to 2.2

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Cardiovascular Death and Non-fatal Myocardial Infarction236 of 2,526

226 of 2,526

0.4 points

-1.2 to 2.0

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: deaths from any cause68 of 2,526

87 of 2,526

-0.8 points

-1.7 to 0.2

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Intracranial Haemorrhage0 of 2,526

10 of 2,526

-0.4 points

-0.7 to -0.2

5,052NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

Vericiguat vs Placebo: deaths from any cause553 of 2,526

561 of 2,524

-0.3 points

-2.6 to 2.0

5,050NCT02861534

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Clinical Decision Support for BUP vs Usual Care: Count of Those With Referral to Follow-up for Ongoing MOUD Treatment (Patient Level)367 of 2,787

226 of 2,260

3.2 points

1.4 to 4.9

5,047NCT03658642

Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD

Clinical Decision Support for BUP vs Usual Care: Count of Initiating BUP in the ED With Referral for Ongoing MOUD With User-centered CDS Compared With Usual Care347 of 2,787

271 of 2,260

0.5 points

-1.4 to 2.3

5,047NCT03658642

Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD

Convalescent Plasma Group vs Non-plasma Group: deaths from any cause40 of 402

343 of 4,642

2.6 points

-0.1 to 6.0

5,044NCT04545047

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

Individualized Opioid Prescription Protocol (IOPP) vs Fixed Opioid Prescription: Number of Participants Who Indicated an Improved Global Impression of Change2,436 of 2,528

2,436 of 2,509

-0.7 points

-1.7 to 0.3

5,037NCT04296396

Opioid Prescription After Cesarean Trial

Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause287 of 2,500

309 of 2,535

-0.7 points

-2.5 to 1.1

5,035NCT02867813

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Vericiguat vs Placebo: Number of Participants Who Experienced One or More Adverse Events2,027 of 2,519

2,036 of 2,515

-0.5 points

-2.7 to 1.7

5,034NCT02861534

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Vericiguat vs Placebo: Number of Participants Who Discontinued Treatment Due to an Adverse Event167 of 2,519

158 of 2,515

0.3 points

-1.0 to 1.7

5,034NCT02861534

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Vericiguat vs Placebo: serious adverse events852 of 2,519

897 of 2,515

-1.8 points

-4.5 to 0.8

5,034NCT02861534

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event2,084 of 2,499

2,144 of 2,532

-1.3 points

-3.3 to 0.7

5,031NCT02867813

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events1,045 of 2,499

1,077 of 2,532

-0.7 points

-3.4 to 2.0

5,031NCT02867813

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=87

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03252249-24eac003",
        "title": "3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: All-cause Mortality",
        "summary": "68 of 2526 against 87 of 2526; risk difference -0.8 points, 95% interval -1.7 to 0.2; NCT03252249, Duration of Dual Anti-Platelet Therapy (DUAL-ACS)",
        "record": "/library/comparisons/NCT03252249-24eac003",
        "nct_id": "NCT03252249",
        "kind": "outcome",
        "participants": 5052,
        "risk_difference": {
          "value": -0.00752177355502771,
          "lower": -0.01718004947090889,
          "upper": 0.0020348100889991012
        },
        "group_1": "68 of 2,526",
        "group_2": "87 of 2,526",
        "difference": "-0.8 points",
        "interval": "-1.7 to 0.2",
        "trial_title": "Duration of Dual Anti-Platelet Therapy (DUAL-ACS)"
      },
      {
        "id": "NCT03252249-4d4609c6",
        "title": "3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Thrombotic Stroke",
        "summary": "13 of 2526 against 7 of 2526; risk difference 0.2 points, 95% interval -0.1 to 0.6; NCT03252249, Duration of Dual Anti-Platelet Therapy (DUAL-ACS)",
        "record": "/library/comparisons/NCT03252249-4d4609c6",
        "nct_id": "NCT03252249",
        "kind": "outcome",
        "participants": 5052,
        "risk_difference": {
          "value": 0.0023752969121140144,
          "lower": -0.001257473998289143,
          "upper": 0.0062846706102963
        },
        "group_1": "13 of 2,526",
        "group_2": "7 of 2,526",
        "difference": "0.2 points",
        "interval": "-0.1 to 0.6",
        "trial_title": "Duration of Dual Anti-Platelet Therapy (DUAL-ACS)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=88",
  "request_id": "HVVvjpjUf96XXBGz"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?